Tolvaptan

BNF:

6.3.2

Status:

Red

Decision Date:

September 2015

Comments

RED¹: NICE TA358: for treating autosomal dominant polycystic kidney disease. (Decision date -  November 2015)

 

CCG commissioned drug for autosomal dominant polycystic kidney disease

NHS England commissioned drug for hyponatraemia .

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating

search again